reference/8103710

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8103710

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase I\|Journal Article
endingPage	407
issn	0090-8258
issueIdentifier	2
pageRange	402-407
publicationName	Gynecologic Oncology
startingPage	402
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_22eea0c588aa956d15373bef9ee7922c
bibliographicCitation	Martin LP, Konner JA, Moore KN, Seward SM, Matulonis UA, Perez RP, Su Y, Berkenblit A, Ruiz-Soto R, Birrer MJ. Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecologic Oncology. 2017 Nov;147(2):402–7. doi: 10.1016/j.ygyno.2017.08.015.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4fbebe144fe034f76de1a121a266ca80 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5e00e52be7098b0746e8c9d26c84ec0a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_446b79594802dfc577aa7a37a4b78974 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f17aa1fab06649e02e539c5d7e262058 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c62142707ff04d14c1ea521a18015bc3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fdbf88e3360435195bd927663f659367 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d1790a47401cd8ed0f526ad5772b5afc http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_09c5748153297e043e40705ce9c6bde7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7dabc2660b002f6197f6593463d65e3f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5ce8a750335f89fb435603dc52f39867
date	201711
identifier	https://pubmed.ncbi.nlm.nih.gov/28843653 https://pubmed.ncbi.nlm.nih.gov/PMC6893864 https://doi.org/10.1016/j.ygyno.2017.08.015
isPartOf	https://portal.issn.org/resource/ISSN/0090-8258 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/3932
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine
discusses	http://id.nlm.nih.gov/mesh/M000617500 http://id.nlm.nih.gov/mesh/M0028142 http://id.nlm.nih.gov/mesh/M0013148 http://id.nlm.nih.gov/mesh/M0545594 http://id.nlm.nih.gov/mesh/M0556300
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D010051Q000188 http://id.nlm.nih.gov/mesh/D058975Q000096 http://id.nlm.nih.gov/mesh/D061067Q000008 http://id.nlm.nih.gov/mesh/D009375Q000276 http://id.nlm.nih.gov/mesh/D018796Q000008 http://id.nlm.nih.gov/mesh/D009375Q000188 http://id.nlm.nih.gov/mesh/D010051Q000276 http://id.nlm.nih.gov/mesh/D008453Q000031
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D061067Q000009 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D008453Q000009 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D008453Q000008 http://id.nlm.nih.gov/mesh/D058975Q000276 http://id.nlm.nih.gov/mesh/D058990 http://id.nlm.nih.gov/mesh/D018796Q000009 http://id.nlm.nih.gov/mesh/D000077216
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6653 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8752 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_9053c209fc2e3612f9b0e657464e7b9f http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9603 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7341 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7453 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID91667591

Showing number of triples: 1 to 65 of 65.